In 2018, James P. Allison and Tasuku Honjo received the Nobel Prize in Medicine for the discovery of a tumor therapy through negative immune regulation. Here, the binding between PD1 (Programmed cell death protein 1) and PD-L1 (Programmed cell death protein 1 ligand) is inhibited. CellTrend has discovered autoantibodies against PD1 and PD-L1 in tumor patients and has been granted a European patent for this discovery.
